Prosecution Insights
Last updated: April 19, 2026
Application No. 18/430,680

METHODS FOR SUPPLEMENTING IRON, PROMOTING IRON ABSORPTION, AND/OR IMPROVING SKIN CONDITION BY USING SASKATOON BERRY EXTRACT

Non-Final OA §103
Filed
Feb 02, 2024
Examiner
HOFFMAN, SUSAN COE
Art Unit
1655
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Tci Co. Ltd.
OA Round
1 (Non-Final)
54%
Grant Probability
Moderate
1-2
OA Rounds
3y 0m
To Grant
80%
With Interview

Examiner Intelligence

Grants 54% of resolved cases
54%
Career Allow Rate
572 granted / 1058 resolved
-5.9% vs TC avg
Strong +26% interview lift
Without
With
+25.7%
Interview Lift
resolved cases with interview
Typical timeline
3y 0m
Avg Prosecution
67 currently pending
Career history
1125
Total Applications
across all art units

Statute-Specific Performance

§101
9.5%
-30.5% vs TC avg
§103
34.8%
-5.2% vs TC avg
§102
17.4%
-22.6% vs TC avg
§112
26.9%
-13.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1058 resolved cases

Office Action

§103
DETAILED ACTION 1. The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . 2. Claims 1-15 are currently pending. Election/Restrictions 3. Applicant’s election without traverse of Group I, claims 1-7, in the reply filed on February 12, 2026 is acknowledged. 4. Claims 8-15 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. 5. Claims 1-7 are examined on the merits. Information Disclosure Statement 6. In the Information Disclosure Statement filed November 12, 2024, applicant did not provide a copy of NPL reference number 1. Thus, this reference could not be considered and the citation has been lined through. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. 7. Claim(s) 1-7 is/are rejected under 35 U.S.C. 103 as being unpatentable over Mazza (Journal of Food Science (1982), vol. 47, pp. 1730-1731) in view of Clark (US 2013/0273199). Mazza teaches the use of Saskatoon (Amelanchier alnifolia) berry as an iron supplement in subjects with anemia (see page 1731, second paragraph). The reference does not teach using a water extract from the Saskatoon berry. Clark teaches a nutritional supplement beverage which comprises a Saskatoon berry water extract. The reference teaches that the extract is made by extracting the berry with water for an hour. The reference teaches that the beverage is a good source of minerals including iron (see paragraphs 6, 9, 11, 22, and 56). Thus, it was known in the art prior to the effective filing date that Saskatoon berries were useful in supplementing iron in a subject in need thereof and that water extracts of Saskatoon berries were useful in compositions that provide iron. Given this knowledge, a person of ordinary skill in the art would reasonably expect that a water extract of Saskatoon berries would be useful in supplementing iron in a subject in need thereof. Therefore, based on this reasonable expectation of success, an artisan would have been motivated to supplement iron in a subject using a water extract from Saskatoon berries. The references do not specifically teach extracting the berries using the ratios of water to berry or the temperatures claimed by applicant. However, as discussed in MPEP section 2144.05(II)(A), “Generally, differences in concentration or temperature will not support the patentability of subject matter encompassed by the prior art unless there is evidence indicating such concentration or temperature is critical. ‘[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation.’ In re Aller, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955).” Varying the extraction parameters such as temperature and solvent concentration is not considered to be inventive unless the concentrations and temperatures are demonstrated as critical. In this particular case, there is no evidence that the claimed concentrations or temperatures produces an unexpected result. Thus, absent some demonstration of unexpected results from the claimed parameters, this optimization of extraction parameters would have been obvious before the effective filing date of applicant’s claimed invention. The references do not specifically teach that the administration of the Saskatoon berry extract has all of the same effects on the subject as claimed by applicant in claims 6 and 7. However, a recitation of the intended use of the claimed invention must result in a structural difference between the claimed invention and the prior art in order to patentably distinguish the claimed invention from the prior art. If the prior art structure is capable of performing the intended use, then it meets the claim. The references together teach administering the same composition as claimed to the same subject as claimed. Thus, the effects claimed in claims 6 and 7 should naturally result from the reference administration if applicant’s invention functions as claimed. 8. No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Susan Hoffman whose telephone number is (571)272-0963. The examiner can normally be reached M-Th 8:30am - 5:00pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Anand Desai can be reached at 571-272-0947. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SUSAN HOFFMAN/Primary Examiner, Art Unit 1655
Read full office action

Prosecution Timeline

Feb 02, 2024
Application Filed
Mar 03, 2026
Non-Final Rejection — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12594313
COMPOSITION FOR RELIEVING CARDIOVASCULAR DISEASES OR OSTEOPOROSIS COMPRISING A MIXED EXTRACT OF HOP AND CYNANCHUM WILFORDII AND METHOD FOR TREATING OR ALLEVIATING CARDIOVASCULAR DISEASES OR OSTEOPOROSIS USING THE SAME
2y 5m to grant Granted Apr 07, 2026
Patent 12582674
Methods and Treatment of Trauma
2y 5m to grant Granted Mar 24, 2026
Patent 12569527
TETRASELMIS CHUII (T. CHUII) FOR THE TREATMENT OF MALE INFERTILITY
2y 5m to grant Granted Mar 10, 2026
Patent 12564606
PHARMACEUTICAL COMPOSITION FOR TREATING WOUNDS
2y 5m to grant Granted Mar 03, 2026
Patent 12564551
Composition or oat extract comprising avenanthramide and ß-glucan
2y 5m to grant Granted Mar 03, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
54%
Grant Probability
80%
With Interview (+25.7%)
3y 0m
Median Time to Grant
Low
PTA Risk
Based on 1058 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month